High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O76083. Start with Alzheimer disease, then reuse UniProt O76083 as the stable protein anchor across project notes and exports.
Start with Alzheimer disease, then reuse UniProt O76083 as the stable protein anchor across project notes and exports.
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include EDELINONTRINE, OSORESNONTRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
Review this target as High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, mapped to UniProt O76083. Sequence length is 593 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A as ChEMBL target CHEMBL3535, mapped to UniProt O76083. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A is the right protein anchor across sources, using UniProt O76083 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Alzheimer disease is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O76083 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A |
| UniProt Accession | O76083 |
| Component Type | Protein |
| Sequence Length | 593 aa |
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
Review this target as High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, mapped to UniProt O76083. Sequence length is 593 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include EDELINONTRINE, OSORESNONTRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL6066018 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL6042821 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL5898437 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL5823889 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL5995578 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL5810180 | 10.52 | Ki | 0.03 | Preclinical |
| CHEMBL5791216 | 10.52 | Ki | 0.03 | Preclinical |
| CHEMBL5978036 | 10.4 | Ki | 0.04 | Preclinical |
| CHEMBL5918399 | 10.4 | Ki | 0.04 | Preclinical |
| CHEMBL5792042 | 10.4 | Ki | 0.04 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 136 | 560 | 7.5 |
| cell-based format | 39 | 206 | 7.4 |
| assay format | 31 | 54 | 6.6 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 0 | — |
| single protein format | 2 | 0 | — |
| assay format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 1 | 8.0 |